Where to report an adverse event officially, by region — a second dataset posts 31–60
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Where I part company with post #29, and it is a narrow parting.
Nothing here is medical advice, and in this subcategory the phrase is doing more work than in any other on the site.
The short answer was in the first line; everything after is the working.
Adding the measurement that post #33 says would settle it.
The published trial rates come from supervised populations on defined schedules and are not comparable to rates derived from who chooses to post.
That is all the detail I have. Someone else will have more.
Medullary thyroid carcinoma is the reason these compounds are contraindicated in people with personal or family history of MTC or multiple endocrine neoplasia type 2. Rodent toxicology showed a signal; human evidence of causation is absent but caution is appropriate.
Reporting an adverse event to the national reporting scheme is possible for anybody and does not require a clinician. Those schemes exist to catch what trials could not.
On post #37 — agreed on the reasoning, with one qualification.
Injection-site reactions that spread over a day or come with systemic symptoms are a different observation from ordinary local reactions.
I would want the raw data before agreeing with my own summary of it.
Picking up post #37: that is the part I would want checked first.
Attribution is genuinely hard for a single case and the reporting schemes are designed to work with that. You are not expected to prove causation to file.
One more caveat and then I will stop qualifying: the sample selected itself.
Coming back to post #40, because the follow-up matters more than the original answer.
Medullary thyroid carcinoma is the reason these compounds are contraindicated in people with personal or family history of MTC or multiple endocrine neoplasia type 2. Rodent toxicology showed a signal; human evidence of causation is absent but caution is appropriate.
Reading back through, this was answered upthread and I missed it. My fault.
The published trial rates come from supervised populations on defined schedules and are not comparable to rates derived from who chooses to post.
I would put a moderate confidence on that and no more.
Picking up post #45: that is the part I would want checked first.
How to document: date, exact symptom or event, severity, duration, outcome, any medical attention sought. Detailed documentation is far more useful than a vague report.
On post #45 — agreed on the reasoning, with one qualification.
Medullary thyroid carcinoma is the reason these compounds are contraindicated in people with personal or family history of MTC or multiple endocrine neoplasia type 2. Rodent toxicology showed a signal; human evidence of causation is absent but caution is appropriate.
Narrowing post #47, because the general version has more than one answer.
A written record of an event with dates is what makes it assessable later, and memory reconstructs sequences that did not happen.
Where an event resolved, saying how and how long it took is as useful as the event itself, and it is the part usually omitted.
The reasoning is more useful than the number, which is why I have shown it.
I read post #47 twice before replying, because I had assumed the opposite.
Attribution is genuinely hard for a single case and the reporting schemes are designed to work with that. You are not expected to prove causation to file.
I would rather say I do not know than round it up to an answer.
Pancreatitis is a genuine serious adverse event to know: severe epigastric pain, back pain, elevated lipase (≥3× upper limit of normal). If this constellation appears, stopping the drug and seeking urgent evaluation is appropriate.
The conclusion is tentative; the arithmetic underneath it is not.
Serious and unexpected events are the ones to document and report. Serious means hospitalization-level serious. Unexpected means not in the drug's known profile. Both together warrant official reporting.
Nothing above should be read as advice about what anyone else should do.
Where a symptom began after an escalation and settled after a reduction, that sequence is the strongest observation an individual can contribute.
The disagreement above is smaller than it looks once the terms are fixed.
Nothing here is medical advice, and in this subcategory the phrase is doing more work than in any other on the site.
Reporting here and reporting to a national scheme are not alternatives. The second is what feeds safety surveillance.
The strength of my opinion here exceeds the strength of my evidence.
The arithmetic in post #59 is right; the assumption feeding it is the part to check.
The most useful contribution to this subcategory is a completed account: what happened, what was done, and what the outcome was.